高级检索
当前位置: 首页 > 详情页

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 自然指数

机构: [1]State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Guangzhou, China [2]Nanfang Hospital, SouthernMedical University, Guangzhou, China [3]Kingmed Center for Clinical Laboratory, Guangzhou, China [4]The First People’s Hospital of Foshan, Foshan, China [5]The People’s Hospital of Honghu, Honghu, China [6]The First People’s Hospital of Jingzhou, Jingzhou, China [7]Jingzhou Central Hospital, Jingzhou, China [8]Honghu Traditional Chinese Medicine Hospital, Honghu, China [9]The Second People’s Hospital of Honghu, Honghu, China [10]Department of AppliedBiology and Chemical Technology, Hong Kong Polytechnic University, Hung Hom, Hong Kong, China [11]Department of Computer Science and Technology,Tsinghua University, Beijing, China [12]The Sichuan Provincial Key Laboratory of Human Disease Study, Institute of Laboratory Medicine, Sichuan ProvincialPeople’s Hospital, University of Electronic Science and Technology of China, Chengdu, China [13]Key Laboratory of Molecular Biology on Infectious Diseases,Ministry of Education, Chongqing Medical University, Chongqing, China [14]Center for Biomedicine and Innovations, Faculty of Medicine, Macau Universityof Science and Technology, Macau, China [15]Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
出处:
ISSN:

摘要:
Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection. Initial results of serological surveillance in China provide valuable data for estimation of the cumulative prevalence of SARS-CoV-2 infection in the general population.

基金:
语种:
高被引:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 医学
小类 | 1 区 生化与分子生物学 1 区 细胞生物学 1 区 医学:研究与实验
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 生化与分子生物学 1 区 细胞生物学 1 区 医学:研究与实验
JCR分区:
出版当年[2018]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 CELL BIOLOGY Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
最新[2024]版:
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 CELL BIOLOGY Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2024版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Guangzhou, China [2]Nanfang Hospital, SouthernMedical University, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构: [1]State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Guangzhou, China [2]Nanfang Hospital, SouthernMedical University, Guangzhou, China [14]Center for Biomedicine and Innovations, Faculty of Medicine, Macau Universityof Science and Technology, Macau, China [15]Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2023 今日访问量:0 总访问量:648 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号